Medovate, a UK based medical device development company, has entered into an agreement with Mercury Medical for exclusive distribution of the FDA-cleared device SAFIRA (SAFer Injection for Regional Anesthesia) across the whole of the United States.
The agreement also includes the newly launched SAFIRA Palm Operator which has been launched in the US market to offer anaesthesiologists more versatility and choice when using the SAFIRA regional anaesthesia system.
In California Mercury Medical will also be distributing the SAFIRA NRFit syringe, which provides an alternative to the Luer connection syringes with which the SAFIRA system was originally introduced.
Stuart Thomson, managing director of Medovate, said: “As our company grows, it has been our vision to centralise our USA distribution with a primary distributor to streamline processes and provide a single contact point for clinicians in the US interested in SAFIRA. Mercury Medical have positioned themselves as a US leader in providing technological advances for clinicians in both airway solutions and anaesthesia – a philosophy that aligns very well with Medovate and SAFIRA. We are excited to this partnership with them as primary distributor of our SAFIRA system in the USA and look forward to entering this next phase of our journey.”
Developed with clinicians working in the NHS to promote safer injection during single shot regional anaesthesia peripheral nerve block procedures, the SAFIRA system makes regional anaesthesia a one-person procedure, giving the anaesthesiologist full control of the injection. It includes a built-in safety mechanism to automatically limit injection pressure helping to reduce the risks of nerve damage, promoting patient safety.
Medovate has a co-promotional partnership agreement with Konica Minolta Healthcare Americas to promote best practice in ultrasound guided regional anaesthesia across the US. Mercury Medical is also an appointed distributor for the Konica Minolta SONIMAGE HS2 portable ultrasound system, complementing their appointment as primary distributor of Medovate’s SAFIRA technology.
Dr John Gargaro, president and CEO at Mercury Medical, said: “SAFIRA represents a superior solution by providing efficiency with integrated safety features designed to improve outcomes for patients receiving regional anaesthesia. As a company, Mercury Medical has a rich experience in introducing and training clinicians on innovative, clinically differentiated medical devices. We are well positioned to provide the central point of contact for all of Medovate’s US sales and distribution requirements for a product offering that perfectly aligns with our mission.”
